Mycofeast acquires Daisy Lab, moving a 500 litre lactoferrin programme onto a 16 million litre platform
Mycofeast buys New Zealand lactoferrin developer Daisy Lab, moving a 500 litre programme onto a 16 million litre European fermentation platform.
Mycofeast, a UK industrial biotechnology company, has acquired Daisy Lab, an Auckland based company that uses precision fermentation to make proteins it describes as bioidentical to dairy proteins. The deal was reported on 15 October 2026 by FoodBev Media, Green Queen and vegconomist. Financial terms were not disclosed. Daisy Lab gives the group its first operations in Australasia, and the acquirer frames the move as an entry into Asia Pacific.
Daisy Lab works on recombinant whey proteins, including beta lactoglobulin and lactoferrin, and its most advanced programme is a high yielding bovine lactoferrin. The company has scaled that process to 500 litre fermentation. It also produced recombinant human lactoferrin at laboratory scale, then paused that line of work late last year. Lactoferrin is used in specialised nutrition and health products, and Green Queen puts the cost of purified material at 600 to 2,000 dollars per kilogram, which is why a fermentation route attracts capital at all.
The acquirer brings the part Daisy Lab did not have. Mycofeast was founded in 2023, runs a biotechnology facility in California and operates a fermentation plant in Europe with 16 million litres of capacity. Its portfolio already covers carotenoids, dairy proteins and other biologically produced ingredients, and its innovation platform, Evolutia Bio, combines AI driven discovery, high throughput screening and genetic engineering. Witek Hruzewicz, chief executive of Mycofeast, said of the sector that “The sector has no shortage of exceptional science.” and described the target as “It is highly complementary to what we are building.”
Daisy Lab was not running a sales process, according to Green Queen, and the talks grew out of an existing partner and customer relationship. All three founders, Irina Miller, Nikki Freed and Emily McIsaac, take roles across the wider Mycofeast group, and Miller says the deal brings no layoffs. The lactoferrin programme continues alongside the Evolutia Bio team in California, with the next twelve months set aside for further scale up, regulatory filings, customer trials and transfer of the process to the group's plant. Miller, co-founder and chief executive of Daisy Lab, pointed to the capital the company had struggled to raise and put the reasoning as “What becomes much less rational is trying to build every capability around that technology yourself,” adding that “Mycofeast gives us access to a much broader scientific, manufacturing and commercial platform”. For scale, Green Queen notes that Vivici already holds self affirmed GRAS status in the United States for its bovine lactoferrin, so the regulatory race is under way.
Why it matters for AgTech founders: the scarce asset in precision fermentation is no longer the strain, it is the tank, the dossier and the customer. Daisy Lab had a working bovine lactoferrin process at 500 litres and a credible science team, and it still concluded that building manufacturing, regulatory and commercial capability around that process was the wrong use of its remaining capital. The distance from 500 litres to 16 million is roughly four orders of magnitude, and no seed or Series A closes it in Europe or anywhere else at today's cost of capital. Two practical consequences follow. First, if the plan is to own production, the capacity question belongs in the Series A deck, not the Series B, because the answer determines whether the company is raising equity or project finance, and those are different investors on different timetables. Second, a trade sale to whoever owns the fermenters is now a realistic base case rather than a failure state, which argues for clean cap tables, assignable IP and process documentation good enough to survive a technology transfer. Undisclosed terms on a venture backed company whose chief executive cites capital difficulties are rarely a headline price, and founders should price that honestly when they model the outcome. The upside is equally real: the science travels, the team travels, and a programme that would have stalled for want of a plant now has one.
Mycofeast acquires Daisy Lab, moving a 500 litre lactoferrin programme onto a 16 million litre platform
The UK industrial biotechnology group buys the Auckland precision fermentation company for undisclosed terms, gains its first operations in Australasia, and takes on a bovine lactoferrin programme that had reached 500 litre scale.
Mycofeast, a UK industrial biotechnology company, has acquired Daisy Lab, an Auckland based company that uses precision fermentation to make proteins it describes as bioidentical to dairy proteins. The deal was reported on 15 October 2026 by FoodBev Media, Green Queen and vegconomist. Financial terms were not disclosed. Daisy Lab gives the group its first operations in Australasia, and the acquirer frames the move as an entry into Asia Pacific.
Daisy Lab works on recombinant whey proteins, including beta lactoglobulin and lactoferrin, and its most advanced programme is a high yielding bovine lactoferrin. The company has scaled that process to 500 litre fermentation. It also produced recombinant human lactoferrin at laboratory scale, then paused that line of work late last year. Lactoferrin is used in specialised nutrition and health products, and Green Queen puts the cost of purified material at 600 to 2,000 dollars per kilogram, which is why a fermentation route attracts capital at all.
The acquirer brings the part Daisy Lab did not have. Mycofeast was founded in 2023, runs a biotechnology facility in California and operates a fermentation plant in Europe with 16 million litres of capacity. Its portfolio already covers carotenoids, dairy proteins and other biologically produced ingredients, and its innovation platform, Evolutia Bio, combines AI driven discovery, high throughput screening and genetic engineering. Witek Hruzewicz, chief executive of Mycofeast, said of the sector that “The sector has no shortage of exceptional science.” and described the target as “It is highly complementary to what we are building.”
Daisy Lab was not running a sales process, according to Green Queen, and the talks grew out of an existing partner and customer relationship. All three founders, Irina Miller, Nikki Freed and Emily McIsaac, take roles across the wider Mycofeast group, and Miller says the deal brings no layoffs. The lactoferrin programme continues alongside the Evolutia Bio team in California, with the next twelve months set aside for further scale up, regulatory filings, customer trials and transfer of the process to the group's plant. Miller, co-founder and chief executive of Daisy Lab, pointed to the capital the company had struggled to raise and put the reasoning as “What becomes much less rational is trying to build every capability around that technology yourself,” adding that “Mycofeast gives us access to a much broader scientific, manufacturing and commercial platform”. For scale, Green Queen notes that Vivici already holds self affirmed GRAS status in the United States for its bovine lactoferrin, so the regulatory race is under way.
Why it matters for AgTech founders: the scarce asset in precision fermentation is no longer the strain, it is the tank, the dossier and the customer. Daisy Lab had a working bovine lactoferrin process at 500 litres and a credible science team, and it still concluded that building manufacturing, regulatory and commercial capability around that process was the wrong use of its remaining capital. The distance from 500 litres to 16 million is roughly four orders of magnitude, and no seed or Series A closes it in Europe or anywhere else at today's cost of capital. Two practical consequences follow. First, if the plan is to own production, the capacity question belongs in the Series A deck, not the Series B, because the answer determines whether the company is raising equity or project finance, and those are different investors on different timetables. Second, a trade sale to whoever owns the fermenters is now a realistic base case rather than a failure state, which argues for clean cap tables, assignable IP and process documentation good enough to survive a technology transfer. Undisclosed terms on a venture backed company whose chief executive cites capital difficulties are rarely a headline price, and founders should price that honestly when they model the outcome. The upside is equally real: the science travels, the team travels, and a programme that would have stalled for want of a plant now has one.